Under tremendous pressure to refuel dwindling development pipelines and improve R&D productivity,
pharmaceutical companies are seeking external sources of products and innovation. Biotech companies
offer valuable technologies, targets, and compounds. Pharma companies best able to access
these assets and adopt new business and R&D models to develop them will be most competitive.
Questions Answered in This Report
Pharmaceutical companies are seeking new ways to build early-stage pipelines. What strategies are available to companies to access early-stage products and technologies? What are the benefits and risks of these strategies? What factors drive decision making for choosing strategies?
External sources offer a variety of valuable early-stage assets. What types of assets are available for building early-stage pipelines? Which companies are the most useful sources of these assets? Which pharmaceutical companies are targeting particular types of companies and assets?
Recent high-value deals exemplify different strategies for accessing external sources for building up early-stage pipelines. What corporate strategies do these deals serve? What are the structure and value of these deals? How do these deals illuminate current industry trends and opportunities in building early-stage pipelines?
Scope
The need for innovation in building early-stage pipelines: R&D spending versus productivity,patent expirations, acquisition targets.
Strategies for accessing innovation: Mergers and acquisitions (M&As), corporate partnerships,academic collaborations.
Strategies for building pipelines through partnering: Development compounds, novel targets, technology platforms.
Select deal highlights in building early-stage pipelines: Novel product classes, diseasemodifying drugs, early-stage compounds, programs around novel targets, broad platform technologies, proprietary platform technologies, technologies for drug repositioning, product class diversifi cation.
Technologies of interest: RNA interference (RNAi), microRNA, large molecules, biologics,glycosylation, antisense, oligonucleotides, DNA vaccine immunotherapy, structurebased drug design, deuterium-based dugs.
Industry outlook: Restructuring internal R&D, need for corporate partnerships, reallocation of R&D resources, shifts in industry structure, novel ways to generate external innovation,corporate venture capital.
(0 items)
